Antimicrobial Susceptibility Patterns of Recent Cuban Mycoplasma genitalium Isolates Determined by a Modified Cell-Culture-Based Method.
Isolation of Mycoplasma genitalium from clinical specimens remains difficult and few strains are available for antimicrobial susceptibility testing. We describe the antimicrobial susceptibility of M. genitalium strains grown in Vero cell culture with first- and second- line antibiotics, using a modified cell-culture-based method. Macrolide- and -fluoroquinolone resistance determinants were detected by sequencing of the 23S and parC genes, respectively. Seven strains were examined, including three new, genetically distinct M. genitalium strains isolated from endocervical and urethral swab specimens from Cuban patients together with four reference strains isolated from specimens collected from men in Denmark, Sweden and Australia. Azithromycin was the most active drug against two of the Cuban M. genitalium strains with MICs values of 0.008 mg/liter, however, one strain was macrolide resistant with an MIC of >8 mg/liter, and the A2059G resistant genotype. Ciprofloxacin was the least active antimicrobial drug and moxifloxacin was the most active fluoroquinolone against the new clinical strains, although an MIC of 1 mg/l was found for two strains. However, no relevant parC mutations were detected. MICs for tetracyclines were 0.5-4 mg/liter. Although the number of Cuban strains was low, the results suggest that a single-dose azithromycin treatment could be ineffective, and that a second-line treatment with moxifloxacin, should become an option in Cuba. To our knowledge, this is the first report of isolation and antibiotic susceptibility testing of M. genitalium strains from the Latin-American region, and the first detection of macrolide resistance in such strains.
Pedro Kourí Tropical Medicine Institute, La Habana, Cuba.
Brian A
BA
Mondeja
Pedro Kourí Tropical Medicine Institute, La Habana, Cuba.
Nadia M
NM
Rodríguez
Pedro Kourí Tropical Medicine Institute, La Habana, Cuba.|Biology Faculty, University of Havana, La Habana, Cuba.
Brenda
B
Barroto
Pedro Kourí Tropical Medicine Institute, La Habana, Cuba.
Orestes
O
Blanco
Microbiology and Infection Control, Statens Serum Institut, Copenhagen, Denmark.
Jørgen S
http://orcid.org/0000-0002-7464-7435
JS
Jensen
Int J Antimicrob Agents. 2010 Sep;36(3):255-8
20580532
New Microbes New Infect. 2013 Nov;1(2):22-6
25356322
Antimicrob Agents Chemother. 2005 Dec;49(12):4993-8
16304163
J Antimicrob Chemother. 2015 Sep;70(9):2515-8
25995292
J Clin Microbiol. 2004 Feb;42(2):683-92
14766837
J Clin Microbiol. 1996 Feb;34(2):286-91
8789002
Clin Infect Dis. 2011 Jan 15;52(2):163-70
21288838
J Clin Microbiol. 2013 Jul;51(7):2245-9
23658265
Clin Infect Dis. 2014 Jul 1;59(1):24-30
24729494
Infect Immun. 2012 Nov;80(11):3842-9
22907815
Antimicrob Agents Chemother. 2009 Nov;53(11):4938-9
19738019
Antimicrob Agents Chemother. 2013 Apr;57(4):1772-6
23357772
PLoS One. 2013 Apr 08;8(4):e61481
23593483
Clin Microbiol Rev. 2011 Jul;24(3):498-514
21734246
Clin Infect Dis. 2008 Dec 15;47(12):1546-53
18990060
BMC Infect Dis. 2015 Aug 19;15:343
26286546
J Clin Microbiol. 2012 Nov;50(11):3542-7
22915608
Antimicrob Agents Chemother. 2014 Jun;58(6):3151-6
24637681
PLoS One. 2012;7(4):e35593
22532861
Int J Antimicrob Agents. 2010 Nov;36(5):477-8
20846831
J Clin Microbiol. 2006 Jun;44(6):2078-83
16757601
Clin Infect Dis. 2013 Apr;56(7):934-42
23223595